SBIR/STTR Research Award
Orally available transition state inhibitors for triple negative breast cancer
Award amount
$225,000Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NANOMETICS LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- PM3SN3WEQW86
- Solicitation number
- PA13-089
- Topic code
- NCI
Research abstract
Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the National Institutes of Health. Product and Long-Term Goal: Nanometics is developing a once daily, oral therapeutic, dubbed MTDIA for the treatment of TNBC. MTDIA inhibits a novel target, 5 -methylthioadenosine phosphorylase (MTAP), and disrupts biochemical pathways crucial for cancer growth. Technical Innovation: The MTAP enzyme is a promising new target for anti-cancer therapeutics because its systemic inhibition results in the whole-body accumulation of the 5'-methylthioadenosine (MTA) metabolite, which alters known anti-cancer pathways. Oral dosing with MTDIA is effective against both MTAP-positive and MTAP-n
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
- Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations
- The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer
- A novel small molecule Bax activator as an oral therapeutic for the treatment of lung cancer.
- A repurposed molecule as an oral therapeutic to improve vascular flow in sickle cell disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
15 SBIR/STTR records share this UEI (2011–2023). Reported award amounts total $13,911,499. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services